What Is the Life Expectancy of Someone With Primary Biliary Cirrhosis?

Life expectancy for someone diagnosed with primary biliary cholangitis (PBC, formerly called primary biliary cirrhosis) varies enormously depending on when the disease is caught and how well it responds to treatment. A person diagnosed early and treated with ursodeoxycholic acid (UDCA) who achieves a good biochemical response can have a life span that looks statistically indistinguishable from the general population. A person diagnosed late with advanced fibrosis or who does not respond adequately to therapy faces a considerably shorter outlook. The gap between those two scenarios is what makes this question so hard to answer with a single number, and it is why understanding the factors that move the needle matters far more than memorizing an average.

How the Disease Progresses Without Treatment

PBC moves through recognizable phases: a preclinical stage where antibodies may be detectable but liver function looks normal, an asymptomatic stage where blood tests start to show elevated liver enzymes, a symptomatic stage with fatigue and itching, and eventually liver insufficiency if the disease is not controlled. In older studies conducted before effective treatment was available, transplant-free survival for untreated patients was roughly 79% at five years, 59% at ten years, and 32% at fifteen years. Those numbers paint a sobering picture of what PBC looks like when left unchecked.

A classic study tracking 280 patients for up to 19 years found an average survival of about 12 years from diagnosis, which at the time was nearly double what earlier reports had suggested.¹ Interestingly, the asymptomatic patients in that cohort survived at rates no different from the general population over a 12-year follow-up window. That finding pointed to something important: when PBC is caught before symptoms appear, there can be a long window where the disease barely affects life expectancy at all.

However, the picture gets more complicated with longer follow-up. A large cohort tracked for up to 24 years found that even asymptomatic patients had shorter survival than age- and sex-matched controls, but this difference only became apparent after about 11 years.² The median predicted survival from diagnosis was roughly 16 years for those who were symptom-free at the time versus about 7.5 years for those already experiencing symptoms. A third of the asymptomatic patients remained symptom-free over 12 years, but once symptoms developed, their survival curve mirrored that of people who had symptoms from the start.

The Enormous Impact of UDCA Treatment

UDCA changed PBC from a disease with a grim trajectory into one that many patients can live with for decades. A large analysis from the Global PBC Study Group found that after statistical adjustment, the ten-year transplant-free survival was about 80% in UDCA-treated patients compared to roughly 61% in untreated patients.³ That translates to a halving of the risk of needing a transplant or dying, with a hazard ratio of 0.46 that held across all disease stages. Even patients whose blood tests did not normalize fully on UDCA still did better than those who received no treatment at all.

The real game-changer for individual prognosis, though, is the quality of the biochemical response. Patients who achieve a good response, typically defined by blood markers like alkaline phosphatase and bilirubin falling to near-normal levels within a year or two, can expect survival that is statistically similar to the general population. A Spanish multicenter trial demonstrated this clearly: the transplant-free survival of biochemical responders matched that estimated for the control population, while non-responders fared significantly worse.⁴ This is the single most important concept in PBC prognosis: the disease itself matters less than how your liver responds to therapy.

Why Age at Diagnosis Matters

There is a counterintuitive pattern in PBC: people diagnosed at older ages tend to respond better to treatment and face a smaller relative increase in risk compared to the general population. In a study of age and sex effects on UDCA response, patients older than 65 had more than five times the odds of achieving a biochemical response compared to patients 45 or younger.⁵ The relative hazard of transplant or death compared to the general population was dramatically higher for young patients: those 35 or younger faced a hazard ratio of about 14.6, while those over 65 had a hazard ratio of only 1.4.

This does not mean younger patients have a shorter total lifespan than older patients in absolute terms. What it means is that being diagnosed young with PBC takes a larger bite out of your expected years. A 30-year-old with PBC faces decades of potential disease progression, and the disease cuts more deeply into a lifespan that otherwise would have been very long. A 70-year-old diagnosed with PBC who responds to UDCA may see almost no measurable impact on their remaining years.

A Hong Kong cohort study illustrated the absolute numbers from a different angle: the median life expectancy of PBC patients in that study was about 71.5 years, compared to over 81 years for men and 87 years for women in the general Hong Kong population.⁶ That is a meaningful gap, but it reflects the full range of disease severity in the cohort, including patients diagnosed late. It is not the expected outcome for someone diagnosed early and well managed.

Predicting Your Individual Outlook

Doctors now have validated scoring tools that can estimate an individual patient’s risk of disease progression. The two most widely used are the GLOBE score and the UK-PBC risk score, both of which use a combination of blood test results after about a year of UDCA treatment to predict long-term outcomes. A U.S. validation study confirmed that both tools have strong predictive ability, with the UK-PBC score performing particularly well.⁷ A separate study found that both scores reliably predicted who would go on to develop decompensation or need a transplant, even among patients receiving combination therapy with UDCA and fenofibrate.⁸

In practical terms, this means your hepatologist can give you a reasonably reliable picture of your personal trajectory after about a year on treatment. A patient with a low risk score at the 12-month mark can feel genuinely reassured. A patient with a high score should be moved to second-line therapy promptly rather than watching and waiting.

When UDCA Is Not Enough

Somewhere between a quarter and a third of patients do not achieve an adequate biochemical response to UDCA alone. For those patients, prognosis without additional therapy is worse, and the push toward second-line options has accelerated in recent years. Obeticholic acid was the first approved second-line drug and has been linked to improved long-term clinical outcomes, though it often worsens itching. Two newer drugs, elafibranor and seladelpar, were recently approved and act through a different mechanism. Off-label use of fibrates like bezafibrate and fenofibrate has also shown biochemical improvements and may help with pruritus rather than worsen it.⁹

A systematic review comparing these second-line agents found that all three approved options significantly increased the chance of biochemical response compared to placebo.¹⁰ The evidence on whether these biochemical improvements translate into decades of extra transplant-free survival is still accumulating, but the direction is clearly positive. The expanding treatment toolkit means that the old survival statistics, drawn largely from the era of UDCA-only therapy, probably overstate the risk for patients diagnosed today.

The Role of Disease Stage and Fibrosis

How much scarring is already present in the liver at diagnosis matters a great deal. Patients with biopsy-confirmed stage III or IV fibrosis have roughly 1.7 to 1.8 times the risk of disease progression compared to those at stage I.¹¹ Among patients starting at early histological stages, about a third progressed from early to moderate disease within three years, and about 44% within five years. For those who already had advanced fibrosis, the five-year progression rate climbed to around 60%.

Fibrosis progression itself is closely tied to treatment response. Patients who failed to bring their alkaline phosphatase down adequately within two years of starting UDCA had dramatically higher odds of worsening fibrosis. Loss of bile ducts in the initial biopsy was also an independent predictor of histological progression.¹² All of this reinforces the same theme: how your liver responds to treatment is the strongest signal for what comes next.

Sex Differences in Prognosis

PBC overwhelmingly affects women, with roughly nine women diagnosed for every man. But the men who do develop PBC tend to have a worse time of it. Male patients are more likely to show advanced fibrosis at diagnosis, to have worse prognostic scores, and to develop hepatocellular carcinoma (liver cancer). In one study, liver cancer was observed only in the male patients.¹³ This does not mean women with PBC are in the clear, but it is worth knowing that the small number of men affected tend to present later and face higher complication rates.

Hepatocellular Carcinoma Risk

Liver cancer is a concern for anyone with chronic liver disease, and PBC is no exception. A population-based study of more than 3,000 PBC patients found that the incidence of hepatocellular carcinoma was about 1.4%, which translated to a roughly 30-fold increase in risk compared to matched controls without liver disease.¹⁴ That sounds alarming, but the baseline rate of liver cancer in the general population is very low, so even a 30-fold increase leaves the absolute risk modest for most PBC patients.

The risk is concentrated among those with advanced disease. A comparative study from Barcelona and Padova found that the incidence of hepatocellular carcinoma ran at about 0.35 to 0.37 per 100 patient-years, and advanced histological stage was the main risk factor.¹⁵ Older age and male sex also raised the risk.¹⁶ For patients with early-stage PBC who are responding well to treatment, routine liver cancer screening is still recommended but the actual probability remains low.

When a Liver Transplant Becomes Necessary

For the subset of patients who progress to end-stage liver disease despite medical therapy, transplantation remains an option with good outcomes. Five-year patient survival after transplant for PBC runs around 81 to 86%, and one-year survival is above 90%.¹⁷ These are among the best outcomes for any liver transplant indication. A large registry analysis comparing living-donor and deceased-donor transplants found ten-year patient survival of about 77% with living donors and 71% with deceased donors.¹⁸

PBC can recur in the transplanted liver. About 22% of patients showed evidence of recurrence at five years and 36% at ten years. Recurrence was associated with a roughly doubled risk of graft loss and a significantly higher risk of death. Median overall survival was about 15 years in patients with recurrence compared to 19 years in those without it.¹⁹ Recurrence is a real issue, but even with it, most transplanted PBC patients live for well over a decade post-transplant.

The AMA-Negative Question

Most PBC patients test positive for antimitochondrial antibodies (AMA), the hallmark blood marker of the disease. A small fraction are AMA-negative, which sometimes causes diagnostic confusion. Whether AMA status affects prognosis has been debated. An older study suggested that AMA-negative patients had worse survival free of liver complications.²⁰ But more recent and larger analyses have found no significant difference. A study specifically looking at patients who already had cirrhosis found that rates of liver-related death, decompensation, and liver cancer were statistically similar between AMA-negative and AMA-positive patients after adjusting for confounders.²¹ An earlier historical cohort study reached a similar conclusion: the clinical course did not differ substantially between the two groups.²² If you are AMA-negative, the current weight of evidence suggests your long-term outlook is essentially the same.

Autoimmune Overlap and Coexisting Conditions

PBC rarely travels alone. Many patients have additional autoimmune conditions such as Sjögren syndrome, autoimmune thyroid disease, or autoimmune hepatitis overlap. Whether these extra diagnoses worsen PBC prognosis is not entirely settled. A retrospective study found that patients with PBC plus autoimmune hepatitis overlap or PBC plus Sjögren syndrome had shorter overall survival than those with PBC alone.²³ However, a separate study looking specifically at extrahepatic autoimmune diseases found no difference in biochemical response rates, hepatic events, or transplant-free survival.²⁴ The discrepancy likely comes down to which overlap condition is present and how severe it is. Autoimmune hepatitis overlap is a liver-specific problem that directly affects the same organ, so it makes sense that it would carry extra risk, whereas thyroid disease or dry eyes probably do not change your liver’s trajectory.

Metabolic Health and Lifestyle

PBC is an autoimmune disease, so you cannot exercise or diet your way out of it. But metabolic factors appear to influence how the disease progresses. A study of nearly 800 PBC patients found that hypertension was associated with a higher risk of liver-related death, while, surprisingly, hyperlipidemia was linked to lower risk of adverse liver outcomes.²⁵ That cholesterol finding may seem paradoxical, but elevated cholesterol is common in PBC and may partly reflect preserved liver function rather than cardiovascular danger. What it does not mean is that high cholesterol is protective in itself.

Research has also flagged that PBC patients, like the general population, tend to have dietary and physical activity patterns that place them at risk for fatty liver disease on top of their autoimmune liver condition.²⁶ Adding a second form of liver injury on top of PBC is something worth avoiding. Maintaining a reasonable body weight, staying physically active, and managing blood pressure are sensible steps that support overall liver health even if they do not change the autoimmune process itself.

What Happens When Cirrhosis Decompensates

The hardest conversations happen when PBC has already progressed to decompensated cirrhosis, meaning the liver can no longer keep up with its basic functions and complications like fluid retention, bleeding, or confusion start to appear. A study of 42 PBC patients who reached this point found that only about 17% achieved what researchers call recompensation, meaning the liver stabilized enough to regain some function. Even among those who recompensated, more than half went on to develop further complications like liver cancer or portal vein clots, and some ultimately died.²⁷ At this stage, transplant evaluation becomes urgent rather than theoretical.

The prognosis at this end of the spectrum is genuinely difficult, but it is also increasingly uncommon for patients who are diagnosed and treated early. The whole trajectory of PBC management has shifted toward catching the disease in its early biochemical stages, getting patients on UDCA promptly, adding second-line therapy for inadequate responders, and reserving transplantation for the small fraction who progress despite everything. For someone newly diagnosed today with early-stage disease and a good response to treatment, the honest answer to the life expectancy question is: probably not much different from anyone else your age.